Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 347

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 347
---
 fees, as these represent significant costs affecting the Company’s consummation of the Business Combination. Other general and administrative expenses, including accounting expenses, printing expenses, and regulatory filing fees, are reviewed in aggregate to ensure alignment with budget and contractual obligations. These expenses are monitored to manage and forecast cash available to complete a business combination within the required period.

All other segment items included in net income or loss are reported on the statement of operations and described within their respective disclosures.

F-100

NOTE 12. SUBSEQUENT EVENTS The Company’s management has evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events other than the below that would have required adjustment or disclosure in the financial statements. On January 7, 2025, the Company obtained additional advances under the Liminatus unsecured promissory note of $ 250,000, which resulted in a total outstanding principal balance of $ 3,918,500. On February 3, 2025, the Company paid $ 739,195to the shareholders whom redeemed their shares on December 20, 2024. On February 3, 2025, the Company withdrew $ 15,000from the Trust account for the payment of taxes. On February 13, 2025, the Company obtained additional advances under the Liminatus unsecured promissory note of $ 125,000which resulted in a total outstanding principal balance of $ 4,043,500. On March 4, 2025, stockholders holding 59,844public shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $ 11.74per share, for an aggregate redemption amount of approximately $ 702,359. On March 7, 2025, the Company obtained additional advances under the Liminatus unsecured promissory note of $ 200,000which resulted in a total outstanding principal balance of $ 4,243,500. On March 31, 2025, the Board of Directors extended the date by which the Company must complete a Business Combination to June 30, 2025. On April 3, 2025, the Company obtained additional advances under the Liminatus unsecured promissory note of $ 200,000which resulted in a total outstanding principal balance of $ 4,443,500.

<div align='center'>F-